A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A2A antagonists

Journal of Neuroscience

Volumn 23, Issue 12, 2003, Pages 5361-5369

  Blum, David ^a   Galas, Marie Christine ^a   Pintor, Annita ^b   Brouillet, Emmanuel ^c   Ledent, Catherine ^a   Muller, Christa E ^d   Bantubungi, Kadiombo ^a   Galluzzo, Mariangela ^b   Gall, David ^a   Cuvelier, Laetitia ^a   Rolland, Anne Sophie ^a   Popoli, Patrizia ^b   Schiffmann, Serge N ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

3 nitropropionic; A2A receptors; Cell death; Huntington's disease; Neuroprotection; Striatum

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 (3 HYDROXYPROPYL) 8 (3 METHOXYSTYRYL) 7 METHYL 1 PROPARGYLXANTHINE; 3 NITROPROPIONIC ACID; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; GLUTAMIC ACID; HUNTINGTIN; MUTANT PROTEIN; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DRUG EFFECT; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL NECROSIS; NEUROMODULATION; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR DENSITY; SIGNAL TRANSDUCTION;

EID: 0038113064     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.23-12-05361.2003     Document Type: Article

References (51)

1. Beal MF (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298-304.
2. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192.
3. Blum D, Gall D, Cuvelier L, Schiffmann SN (2001) Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport 12:1769-1772.
4. Blum D, Galas MC, Gall D, Cuvelier L, Schiffmann SN (2002a) Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiol Dis 10:410-426.
5. 1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 22:9122-9133.
6. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN (2003) Adenosine receptors in Huntington's disease. Lancet Neurol 2:366-374.
7. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105-7109.
8. Brouillet E, Guyot MC, Mittoux V, Altairac S, Conde F, Palfi S, Hantraye P (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem 70:794-805.
9. Brouillet E, Conde F, Beal MF, Hantraye P (1999) Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59:427-468.
10. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646-653.
11. Calabresi P, Gubellini P, Picconi B, Centonze D, Pisani A, Bonsi P, Greengard P, Hipskind RA, Borrelli E, Bernardi G (2001) Inhibition of mitochondrial complex lI induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J Neurosci 21:5110-5120.
12. 2A agonist, ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion. J Vasc Surg 34:482-488.
13. Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney Jr JB, Davies SW, Bates GP, Young AB (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci 354:981-989.
14. 2A adenosine receptor deficiency attenuates brain injury induced by transient focalischemia in mice. J Neurosci 19:9192-9200.
15. 2A adenosine receptors in rescuing the nerve growth factor-induced neurite outgrowth impaired by blockage of the MAPK cascade. J Biol Chem 277:33930-33942.
16. 2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats. NeuroReport 11:2591-2595.
17. 2A receptors. J Neurochem 78:183-198.
18. El Massioui N, Ouary S, Cheruel F, Hantraye P, Brouillet E (2001) Perseverative behavior underlying attentional set shifting deficit in rats chronically treated with the neurotoxin 3-nitropropionic acid. Exp Neurol 172:172-181.
19. 2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 438:183-188.
20. 2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci 55:L61-L65.
21. A receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97:505-519.
22. Guyot MC, Palfi S, Stutzmann JM, Maziere M, Hantraye P, Brouillet E (1997) Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Neuroscience 81:141-149.
23. 2A receptors in the caudate-putamen of rats. Eur J Neurosci 14:1287-1293.
24. 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431:331-346.
25. 2 receptors. J Biol Chem 277:18091-18097.
26. The Huntington's Disease Study Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72:971-983.
27. Ikonomidou C, Stefovska V, Turski L (2000) Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc Natl Acad Sci USA 97:12885-12890.
28. 2A receptor antagonist. Brain Res 800:328-335.
29. 2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology, in press.
30. 2A receptor in basal ganglia. Biosci Biotechnol Biochem 65:1447-1457.
31. 2A receptor. Nature 388:674-678.
32. Lee FS, Chao MV (2001) Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc Natl Acad Sci USA 98:3555-3560.
33. 2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br J Pharmacol 136:434-440.
34. 2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49:727-735.
35. 2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther 285:9-15.
36. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. NeuroReport 9:3955-3959.
37. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-920.
38. Ouary S, Bizat N, Altairac S, Menetrat H, Mittoux V, Conde F, Hantraye P, Brouillet E (2000) Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97:521-530.
39. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736.
40. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Orlando, FL: Academic.
41. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur J Pharmacol 287:215-217.
42. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci 22:1967-1975.
43. 2 receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. Brain Res 831:315-318.
44. 2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17:82-91.
45. Sanchez-Carbente MR, Massieu L (1999) Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired. J Neurochem 72:129-138.
46. Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler Jr JF, Greenamyre JT, Snyder SH, Ross CA (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 5:1194-1198.
47. 2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J Neurosci 13:1080-1087.
48. 2A receptors. Prog Neurobiol 59:355-396.
49. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45:25-32.
50. 2A receptor signaling in striatal cells expressing mutant huntingtin. FASEB J 15:1245-1247.
51. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.